Our 2020 volunteer award winners have been announced
Parkinson's didn't stop for coronavirus, and neither did we. Here are the three things we’re most proud of this year, and how you can get involved in 2021.
People with Parkinson’s are losing an average of two and a half hours a day to debilitating symptoms when their medication wears off, a Parkinson’s UK survey has found.
Our recent survey has found that nearly three quarters (74%) of people on Parkinson's medication experience 'wearing off', when symptoms including pain, stiffness and tremors become worse between doses.
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.
After 15 years leading the charity, Steve Ford is saying a fond farewell to Parkinson's UK at the end of January 2021. He'll then start his search for a new challenge.
Find out about a parliamentary committee we gave evidence to about the impact of coronavirus on people with Parkinson’s
Parkinson's UK supporter Paul Mayhew-Archer reflects on his MBE in the honours list.
We're funding a new research study into a possible treatment for hallucinations in Parkinson's.
Researchers in the US have uncovered a link between long-term exposure to pollution and deterioration in health conditions. This includes Parkinson's and Alzheimer's.
Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
Sharing the results of the 'What Matters Most?' survey and coronavirus poll that have determined our campaigning priorities for the next four years
Simvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.
Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.